The Relative Strength (RS) Rating for Kymera Therapeutics climbed into a new percentile Wednesday, as it got a lift from 62 to 71.
When To Sell Stocks To Lock In Profits And Minimize Losses
This exclusive rating from Investor's Business Daily tracks share price action with a 1 (worst) to 99 (best) score. The score shows how a stock's price performance over the trailing 52 weeks compares to all the other stocks in our database.
Over 100 years of market history reveals that the best-performing stocks tend to have an RS Rating of at least 80 as they begin their largest climbs. See if Kymera Therapeutics can continue to show renewed price strength and hit that benchmark.
Kymera Therapeutics is trying to complete a consolidation with a 50.27 entry. See if the stock can clear the breakout price in volume at least 40% above average.
The company reported 0% earnings growth in the latest quarterly report, while sales growth came in at -55%.
The company holds the No. 281 rank among its peers in the Medical-Biomed/Biotech industry group. Aurinia Pharmaceuticals, Halozyme Therapeutics and argenx ADR are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Stocks With Rising Relative Strength Ratings
